Sofia Noori, Nema Health

Key Takeaways

• ICPT claims 99% PTSD cure rate in <30 days
• Study conducted by Nema Health, led by CEO Sofia Noori
• Technique combines intensive therapy sessions with digital monitoring
• Potential to disrupt pharma‑centric PTSD treatment landscape
• Regulatory approval and scalability remain unanswered questions

Summary

Nema Health announced that its intensive cognitive processing therapy (ICPT) achieved a reported 99% cure rate for post‑traumatic stress disorder (PTSD) within a month, according to a new study. The findings were presented by CEO and psychiatrist Sofia Noori, who demonstrated the therapy’s workflow and outcomes. The claim positions Nema’s solution as a potentially transformative, rapid‑response alternative to traditional, longer‑duration PTSD treatments. The announcement was highlighted in a health‑tech column on February 17, 2026.

Pulse Analysis

Post‑traumatic stress disorder remains a leading cause of disability, affecting millions worldwide and often requiring years of psychotherapy or medication. Conventional approaches such as prolonged exposure therapy or selective serotonin reuptake inhibitors deliver modest remission rates and can be costly for both patients and insurers. In this context, any breakthrough that promises rapid, durable symptom resolution garners intense interest from clinicians, payers, and investors seeking to alleviate the chronic burden of PTSD.

Nema Health’s intensive cognitive processing therapy (ICPT) purports to compress the therapeutic timeline into a single month, delivering a 99% cure rate in its internal study. The protocol blends high‑frequency, therapist‑guided cognitive processing sessions with real‑time digital monitoring tools that track physiological and emotional markers. CEO Sofia Noori, a board‑certified psychiatrist, emphasized the data’s robustness, noting that participants showed sustained symptom remission across standardized PTSD scales. If validated, the model could redefine best‑practice guidelines, positioning technology‑augmented intensive therapy as a viable first‑line option.

The broader implications extend beyond clinical outcomes. A rapid, highly effective PTSD treatment could slash long‑term healthcare expenditures, reduce reliance on psychotropic drugs, and accelerate patients’ return to productivity. However, the claim raises questions about regulatory clearance, scalability of therapist‑intensive delivery, and real‑world efficacy across diverse populations. Stakeholders will watch forthcoming peer‑reviewed publications and potential FDA submissions closely, as Nema Health’s approach may catalyze a new wave of evidence‑based, tech‑driven mental‑health interventions.